
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934**

For the month of February 2009

Commission File Number 000-28508

Flamel Technologies S.A.

(Translation of registrant's name into English)

**Parc Club du Moulin à Vent
33 avenue du Dr. Georges Levy
69693 Vénissieux Cedex France**
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark whether registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _____

INFORMATION FILED WITH THIS REPORT

Document Index

99.1 Press release regarding appointment of Jeffrey S. Vick as Chief Business Officer, dated February 23, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Flamel Technologies S.A.

Dated: February 23, 2009

By: /s/ Stephen H. Willard

Name: Stephen H. Willard

Title: Chief Executive Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press release regarding appointment of Jeffrey S. Vick as Chief Business Officer, dated February 23, 2009.



FLAMEL TECHNOLOGIES

Flamel Technologies Announces Appointment of Jeffery S. Vick as Chief Business Officer

LYON, France – February 23, 2009 – Flamel Technologies S.A. (Nasdaq: **FLML**) today announced that Jeffery Vick has joined its senior management team as Flamel's Chief Business Officer. Mr. Vick previously served as Chief Executive Officer of Silence Therapeutics plc, a leading European RNAi company. Mr. Vick received his MBA from Stanford University, his MS in Chemistry from the University of California, San Diego, and brings to Flamel over twenty years experience in the pharmaceutical and biotechnology industries.

"Jeff's expertise in corporate development, market research, and intellectual property issues has been developed both in Europe and in the U.S.," remarked Stephen H. Willard, the Company's chief executive officer. "His background in these areas, together with his history of doing fundamental research in oncology and his work in developing biotechnology, drug delivery and genomics companies, makes him an ideal addition to the Flamel team. My colleagues and I are greatly looking forward to Jeff's assistance in building upon Flamel's existing relationships with our pharmaceutical and biotechnology partners and in developing new ones."

"Flamel's technology platforms are ideally positioned to provide important solutions to the pharmaceutical and biotechnology industries. These extend to efficacy and safety, but also to important issues in drug development such as stabilization and the extension of effective half-life without affecting bioactivity," said Mr. Vick. "I am particularly pleased to be joining a company which enjoys tremendous growth opportunities coupled with a solid financial foundation."

Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Micropump® is a controlled release and taste-masking technology for the oral administration of small molecule drugs. Flamel's Medusa® technology is designed to deliver controlled-release formulations of therapeutic proteins and peptides.

Contact:

Charles Marlio, Director of Strategic Planning and Investor Relations

FRANCE: + 33-4-72-78-34-34

Marlio@flamel.com

This document contains a number of matters, particularly as related to the status of various research projects and technology platforms, that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The document reflects the current view of management with respect to future events and is subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel's reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel's Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 2007.